UWM Foundation UWM Research Foundation UWM Real Estate Foundation UWM Alumni Association
mobile logo

Two UWM Startups Receive Bridge Grants to Fuel Next Phase of Growth

by Jane L.
Bridge Grant Program, Chemistry, Engineering, For Industry, For Researchers, For Startups, Funding, Healthcare, Innovations, Startups
04/07/2026

Since 2021, the UWMRF Bridge Grant program has helped high-potential startups at the University of Wisconsin-Milwaukee (UWM) overcome early funding gaps and accelerate toward growth. With the support of generous community partners, the program has awarded $600,000 to 14 UWM-affiliated startups over the past five...

UWM Research Foundation Announces New Catalyst Grants

by UWMRF
Bioscience, Catalyst Grant Program, Chemistry, Engineering, Healthcare
09/19/2018
The UWM Research Foundation is proud to announce four Catalyst Grants for projects that include a new purification system for antibodies; online self-administered diagnostic program for psychiatric disorders; a power hand rehabilitation glove for home use; and an easier two-line breeding system for sorghum hybrids. These projects feature strong research teams and three new researchers that have not been previously funded.
Continue reading

Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

by UWMRF
Chemistry, Drug Discovery, News
11/20/2017
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023. Promentis is developing SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders. SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies.
Continue reading